4134results about How to "Reduce stimulation" patented technology

A repeater system may control a pump by using a repeater and a user interface. An adhesive patch system may be used for affixing a pump or other object to a human body. Such an adhesive patch system may include two sets of adhesive members, each member including an adhesive material on at least one side so as to attach to the body. The members of the first set are spaced to allow the members of the second set to attach to the body in spaces provided between the members of the first set, and the members of the second set are spaced to allow members of the first set to detach from the body without detaching the members of the second set. Also, fill stations and base stations are provided for personal pump systems.

An agent delivery or sampling device (2) comprising a member (6) having a plurality of blades (4) for piercing the skin and a connecting medium (65) covering at least a part of the skin contacting side (48) of the member (6) for increasing transdermal flux of an agent.

The addition of low concentrations of combinations of water-soluble organic salts of zinc to gels, creams, lotions or ointments can increase the ability of these products to reduce or prevent exogenous irritants from causing irritation of the underlying substrate. The addition of low concentrations of combinations of water-soluble organic zinc salts to these gels, creams, lotions or ointments also can reduce the irritation of skin or mucous membranes caused by the addition of potentially-irritating substances such as spermicides, microbicides, fungicides or other therapeutic agents to the gel, cream, lotion or ointment. The advantages of this anti-irritant approach over others, which generally employ high concentrations of single zinc salts, are the reduced potential for zinc toxicity, the reduced potential for toxicity related to zinc itself, and the preservation of the desirable biological properties of potentially-irritating therapeutic substances added to the gel, cream, lotion or ointment.

A spinal fixation assembly has a bone screw with head having a continuously curved spherical outer surface. The curved surface nests in a split annular bushing having a plurality of segments curving around the screw head. The bushing has an outward extending flange that fits into a recess in a socket in a fixation plate. The plate has at least three legs which extend from ends of a cross-member to form one of an H shaped, X shaped or A shaped configuration. Each socket is curved to rotatably receive rotation of the bushing. The socket recess is larger than the bushing flange to allow the bushing to tilt a predetermined amount depending on a thickness of the outward extending flange.

The present invention relates to pharmaceutical compositions useful for topical, non-invasive delivery of an oligonucleotide to the ear and to methods for the treatment of an ear disorder, including hearing loss arising from chemical-induced ototoxicity, acoustic trauma and presbycusis; and microbial infections. The method comprises topically administering to the ear of a subject in need thereof a pharmaceutical composition comprising an inhibitory oligonucleotide, a permeability enhancer and a pharmaceutically acceptable carrier, wherein the oligonucleotide reduces or inhibits expression of a gene associated with the ear disorder in the subject.

A cushion for a patient interface includes two or more bladders arranged in concentric relation. Each of the bladders includes a face-contacting portion adapted to engage the patient's face, and each of the bladders is adapted to be pressurized independently from one another. At least one of the bladders is an active bladder that is pressurized to at least a sealing pressure to form a continuous seal with the patient's face in use.

The present invention relates to methods and compositions which employ low concentrations of combinations of zinc salts to prevent the irritation of skin or mucous membranes that may be caused by therapeutic agents, by personal hygiene products, or by various physical, chemical, mechanical, or biological irritants, including infectious agents.

An artificial cornea comprising an optical element made of an optically transparent material, having a front surface and a posterior surface, and a skirt provided so as to support with surrounding at least a part of the optical element, characterized in that the skirt is provided with a flange on its side facing the interior of eyes during implantation of the artificial cornea and the flange radially protrudes outward from the skirt. The artificial cornea can be well compatible with ocular tissue, prevent leakage of intraocular aqueous humor and intraocular invasion of bacteria, reduce stimulation on palpebral conjunctiva and further, inhibit progression of the down growth, and which has no possibility of reduction in transparency of the optical element due to the down growth as well as detachment and extrusion from the implanted state.

For use in controlling the release of aqueous from anterior chamber of the eye, a surgically implantable flow regulating implant is provided which is assembled in parts from a molded elastomeric plate, a flow regulating member and drainage tube. The elastomeric plate contains a pocket, a circular passageway and slots. The flow regulating member includes tabs and a resilient membrane, said tabs are securely attached to the plate inside the slots to support the membrane. The membrane being generally arch-shaped completely covers the pocket forming a releasable seal between the said pocket and outer surface of the said plate.

The invention relates to the essential oil of tobaccos as well as a preparation method and application thereof to cigarettes. The essential oil of the tobaccos is prepared by the following method of: taking discarded/defective tobacco wastes, extracting by an organic solvent, taking the crude extract of the essential oil, introducing water vapor, condensing and separating oil and water so as to obtain the essential oil of the tobaccos. By adding the essential oil of the tobaccos, which is disclosed by the invention and is used as a flavoring agent, into the tobacco shreds of cigarettes, the self fragrance of the tobaccos can be increased, the quality of the fragrance of the cigarettes is enhanced, the excitation and the miscellaneous gas of the tobaccos are reduced, and smoke is softened. The essential oil of the tobaccos as well as the preparation method and the application thereof to the cigarettes have the advantages that the advantage of higher extracting yield of a solvent extracting method and the characteristic of refinement of a water-vapor distillation extracting method are combined, the yield of the essential oil of the tobaccos is obviously higher than that of a traditional water-vapor distillation method, and extracting equipment and a solvent are simple and convenient and are easy to obtain; and moreover, no solvent residue exists in a final product of the essential oil of the tobaccos, and the safety of the product is high.

The present invention relates to polypeptide-polysiloxane copolymers, to their preparation by thermal copolymerization of amino acids with organofunctional polysiloxanes, and to their use as interface-active substances. The polypeptide-polysiloxane copolymers consist of at least one polysiloxane unitand of at least one polypeptide unit

The invention relates to a spectacle lens capable of preventing blue light radiation and eliminating the chromatic aberration and a manufacture method thereof, which belongs to the technical field of spectacles and the manufacture method thereof. The spectacle lens is characterized in that a substrate is prepared from an organic polymer, a blue light absorbent and a UV absorbent by mixing; and a coated film layer includes a TiO2 layer, an Al2O3 layer, an ITO layer, a noble metal layer, an MgF2 layer and a SiO2 layer. The manufacture method of the spectacle lens comprises following steps of: preparing materials, mixing, stirring, curing, cleaning the substrate, reinforcing and coating film on the substrate. The spectacle lens capable of preventing blue light radiation and eliminating the chromatic aberration can effectively filter most of UV light and a portion of blue light to reduce the damage to human retina and the irritation of shortwave glare, thus reducing chromatic aberration and improving resolution of human eyes. Accordingly, persons wearing the spectacle lens can view objects clearly in weaker or stronger light environment.

Described herein are Transcranial Magnetic Simulation (TMS) systems and methods of using them for emitting focused, or shaped, magnetic fields for TMS. In particular, described herein are arrays of TMS electromagnets comprising at least one primary (e.g., central) TMS electromagnet and a plurality of secondary (e.g., lateral or surrounding) TMS electromagnets. The secondary TMS electromagnets are arranged around the primary TMS electromagnet(s), and are typically configured to be synchronously fired with the primary TMS electromagnets. Secondary TMS electromagnets may be fired at a fraction of the power used to energize the primary TMS electromagnet to shape the resulting magnetic field. The secondary TMS electromagnets may be stimulated at opposite polarity to the primary TMS electromagnet(s). Focusing in this manner may prevent or reduce stimulation of adjacent non-target brain regions.

The present invention provides implantable ocular drug delivery devices. Generally, the devices have a distal portion with a coil shaped body member and a proximal portion which contacts the sclera. In one aspect, the coil-shaped body member includes a unique configuration including two coiled portions with different pitches, which improves insertion of the device into the eye. In another aspect, the device has a proximal portion that includes a unique cap configuration having a concave distal face that improves stabilization of the device in the eye. In another aspect, the device includes a transitional portion between the cap and the coil-shaped body member that also improves stabilization of the device in the eye. The invention also provides methods for inserting the medical device into the eye, and methods for the treatment of an ocular condition.

The invention relates to a method of insulin eye drops for treating dry eye syndrome due to any and all etiological factors (Keratoconjunctivitis sicca), including Sjogren's syndrome, Meibomian gland dysfunction (MGD) and other glandular malfunction in the eye lids, lacrimal glands, cornea, conjunctiva, and exposed scleral surface of the eye. It is treated with Insulin and/or IGF-I with or without known anti-dry eye syndrome therapeutic, pharmaceutical, biochemical and biological agents or compounds.

Disclosed is a device and method for improving the facial comfort and sealing ability of a full-face mask comprising a liner of soft material, preferably made from moleskin or the like. The disclosed face mask liner provides a superior feel to the user's face compared with standard face masks with air-filled cushion or silicone gasket cuffs, while providing a more comfortable user experience and a superior seal to prevent loss of breathing gas. Also disclosed is a similar device and method for improving the facial comfort of a nasal mask, providing a mask that is more comfortable to the user.

Cosmetic methods of skin lightening using coumarin derivatives of formula I as skin lightening agents alone or in combination with other skin benefit agents and together with a cosmetic vehicle:

Where each or both R₁ and/or R₂ represents hydrogen; linear or branched C₁-C₁₈ alkyl, alkenyl, cycloalkyl, cycloalkenyl, hydroxyalkyl, hydroxyalkenyl, acyl, cycloacyl, or alkoxy groups;

• • Each or both R₃ and/or R₄, which may be connected by a single or double carbon-carbon bond (shown as a dotted line), represents hydrogen; linear or branched C₁-C₁₈ alkyl, alkenyl, alkoxy, cycloalkyl, or cycloalkenyl group; and
  • Each or both R₅ and/or R₆ represents a hydrogen atom, OH, C₁-C₄ acyl group, C₁-C₄ alkyl group, O—CO—R₇, O—COO—R₈ group, mesyl group or tosyl group, where each or both R₇ and/or R₈ represents hydrogen; linear or branched C₁-C₁₈ alkyl, alkenyl, hydroxyalkyl, hydroxyalkenyl, acyl, cycloacyl, or alkoxy groups.